John Wesolowski - Perrigo Company Executive Vice President and Presidentident - RX

<div class='logoBackup' style='background:#0D8ECF;color: white;font-size:3em;;'>PRG</div>
PRGO -- USA Stock  

Last Earning Anouncement Date: December 31, 2015  

  President
Mr. John Wesolowski is Executive Vice President, President RX of the Company. Mr. Wesolowski was named Executive Vice President, President RX in November 2016. He previously was named as Acting General Manager, RX, in July 2016 and served in that capacity until November 2016. Previously, he served as Senior Vice President of RX Commercial Operations, from 2013 until July 2016
Age: 49  President Since 2016      
353 1 709 4000  http://www.perrigo.com
Wesolowski joined Perrigo in February 2004 as the Vice President, RX Sales and Marketing and was subsequently promoted to the Senior Vice President of RX Sales and Marketing in 2012.

John Wesolowski Latest Insider Activity

John Wesolowski over two weeks ago via Macroaxis 
Perrigo Company exotic insider transaction detected
John Wesolowski over three weeks ago via Macroaxis 
Perrigo Company exotic insider transaction detected

Management Efficiency

The company has return on total asset (ROA) of 2.19 % which means that it generated profit of $2.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.32 % meaning that it created $4.32 on every $100 dollars invested by stockholders.
The company currently holds 3.5 B in liabilities with Debt to Equity (D/E) ratio of 60.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Perrigo Company has Current Ratio of 2.03 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Thomas GraneyVertex Pharmaceuticals Incorpor
2017
Michael AbermanRegeneron Pharmaceuticals
2015
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
Samiran DasDr Reddys Laboratories Ltd
2016
Ganadhish KamatDr Reddys Laboratories Ltd
2016
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Douglas McCorkleRegeneron Pharmaceuticals
2007
Sandra BeatyZoetis
2012
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Glenn DavidZoetis
2016
Jay MarkowitzRegeneron Pharmaceuticals
2017
Roman TrawickiZoetis
2015
Stefan WeiskopfZoetis
2013
Michael PariniVertex Pharmaceuticals Incorpor
2017
Peter PowchikRegeneron Pharmaceuticals
2006
Daniel PlewRegeneron Pharmaceuticals
2016
Paul SilvaVertex Pharmaceuticals Incorpor
2019
Clinton LewisZoetis
2018
Kimberly WhiteVertex Pharmaceuticals Incorpor
2018
Joseph LaRosaRegeneron Pharmaceuticals
2019
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018

Entity Summary

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo Company operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10600 people.Perrigo Company Plc (PRGO) is traded on BATS Exchange in USA and employs 10,600 people.

Perrigo Company Leadership Team

John Hendrickson, President
Gary Cohen, Independent Director
Arthur Shannon, IR Contact Officer
Ronald Winowiecki, Acting CFO
Svend Andersen, Executive Vice President and President - Consumer Healthcare International
Judy Brown, CFO and Executive VP
Laurie Brlas, Independent Director
Donal OConnor, Independent Director
James Michaud, Chief Human Resource Officer, Executive Vice President
Louis Yu, Executive Vice President - Global Quality
John Wesolowski, Executive Vice President and Presidentident - RX
Theodore Samuelsto, Independent Director
Scott Jamison, Executive Vice President General Manager - Nutritionals
Ellen Hoffing, Independent Director
Marc Coucke, Executive Vice President General Manager - Omega Pharma Business
Adriana Karaboutis, Independent Director
Michael Jandernoa, Independent Director
Paul Weninger, Executive Vice President - Global Quality Operations
Thomas Farrington, Senior Vice President CIO
Herman Morris, Independent Director
Jeffrey Needham, Executive Vice President General Manager - Consumer Healthcare
Todd Kingma, Executive VP, General Counsel and Secretary
Rolf Classon, Independent Director
Raymond Silcock, CFO
Shlomo Yanai, Independent Director Nominee
Jatin Shah, Senior Vice President Chief Scientific Officer
Michael Stewart, Senior Vice President - Global Human Resources
Jeffrey Kindler, Independent Director
Jacqualyn Fouse, Independent Director
Grainne Quinn, Executive Vice President Chief Medical Officer
Theodore Samuels, Independent Director
Geoffrey Parker, Independent Director
Murray Kessler, President CEO, Director
Sharon Kochan, Executive VP and General Manager of International
Gary Kunkle, Lead Independent Director
Joseph Papa, Chairman and CEO
Marry Brlas, Independent Chairman of the Board
Bradley Alford, Independent Director
Jeffrey Smith, Independent Director
Bradley Joseph, IR Contact Officer
James Dillard, Executive Vice President Chief Scientific Officer
Douglas Boothe, Executive Vice President General Manager - Rx Pharmaceuticals
Ronald Janish, Executive Vice President - Global Operations and Supply Chain
Uwe Rohrhoff, President CEO, Director

Stock Performance Indicators

Did you try this?

Run Technical Analysis Now

   

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
All  Next Launch Module

Currently Active Assets on Macroaxis

SSM   
Sold over 100K shares of
few days ago
Traded for 0.175
S32   
Purchased over 10K shares of
few days ago
Traded for 2.5
BSL   
Purchased over 100 shares of
few days ago
Traded for 15.49
MBI   
Purchased over 100 shares of
few days ago
Traded for 9.2
MDLZ   
Purchased over 100 shares of
few days ago
Traded for 54.19
Please also check Your Equity Center. Please also try Idea Breakdown module to analyze constituents of all macroaxis ideas. macroaxis investment ideas are predefined, sector-focused investing themes.